Query author contributions in Reactome
Reactome depends on collaboration between our curation team and outside experts to assemble and peer-review its pathway modules. The integration of ORCID within Reactome enables us to meet a key challenge with authoring, curating and reviewing biological information by incentivizing and crediting the external experts that contribute their expertise and time to the Reactome curation process. More information is available at ORCID and Reactome.
If you have an ORCID ID that is not listed on this page, please forward this information to us and we will update your Reactome pathway records.
Details on Person Glycogen storage disease type II (GSD II - Pompe's disease) ...
| Class:Id | Summation:5357614 |
|---|---|
| _displayName | Glycogen storage disease type II (GSD II - Pompe's disease) ... |
| _timestamp | 2018-02-07 21:03:37 |
| created | [InstanceEdit:5357615] D'Eustachio, Peter, 2014-03-25 |
| modified | [InstanceEdit:6790956] D'Eustachio, Peter, 2015-08-15 [InstanceEdit:6791023] D'Eustachio, Peter, 2015-08-17 [InstanceEdit:9036730] D'Eustachio, Peter, 2018-02-07 |
| text | Glycogen storage disease type II (GSD II - Pompe's disease) is caused by mutations that reduce or eliminate the activity of lysosomal alpha-glucosidase (GAA) (Hers 1963). The presentation of GSD II varies with the severity of the mutation: patients with little or no GAA activity are affected shortly after birth and multiple tissues are severely affected. Patients with higher levels of GAA activity present later in life, often with symptoms restricted tocardiac and skeletal muscle (Leslie & Tinkle). At a cellular level, symptoms of the disease are due to accumulation of structurally normal glycogen in lysosomes. Glycogen, thought to enter lysosomes via autophagy, is fully degraded by GAA (Brown et al. 1970), but accumulates if the enzyme is absent or reduced in activity. The two mutant alleles annotated here are associated with near-complete loss of enzyme activity and early onset of disease (Hermans et al. 1991; Zhong et al. 1991). Many other mutant alleles have been described and their residual activities correlated with disease presentation (e.g., Kroos et al. 2012). |
| (summation) | [Pathway:5357609] Glycogen storage disease type II (GAA) [Homo sapiens] |
| [Change default viewing format] | |
